


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER CCP01 P-300
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/524476
INTERNATIONAL APPLICATION NO. PCT/CN03/00664	INTERNATIONAL FILING DATE 13 August 2003 (13.08.2003)	PRIORITY DATE CLAIMED 13 August 2002 (13.08.2002)
TITLE OF INVENTION THE USE OF N-ACETYL-D-GLUCOSAMINE FOR PREPARING MEDICINES FOR UROGENITAL TRACT INFECTION'S TREATMENT AND PREVENTION		
APPLICANT(S) FOR DO/EO/US XU, Qiwang, et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.4. <input checked="" type="checkbox"/> The US has been elected (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto.b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none">11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A preliminary amendment.14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.15. <input type="checkbox"/> A substitute specification.16. <input type="checkbox"/> A power of attorney and/or change of address letter.17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).20. <input checked="" type="checkbox"/> Other items or information: Authorization to Charge Deposit Account		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/524476		INTERNATIONAL APPLICATION NO. PCT/CN03/00664		ATTORNEY'S DOCKET NUMBER CCP01 P-300		
The following fees have been submitted				CALCULATIONS	PTO USE ONLY	
21. <input checked="" type="checkbox"/> Basic national fee..... \$300				\$ 300.00		
22. <input checked="" type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)..... \$100 All other situations..... \$200				\$ 200.00		
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100 International Search Report prepared and provided to the Office..... \$400 All other situations..... \$500				\$ 400.00		
TOTAL OF 21, 22 and 23 =				\$ 900.00		
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE			
8 - 100 =	-92 /50 =		x \$250	\$ 0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$ 0.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
Total claims	9 - 20 =	0	x \$ 50	\$ 0.00		
Independent claims	1 - 3 =	0	x \$200	\$ 0.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$ 0.00		
TOTAL OF ABOVE CALCULATIONS =				\$ 900.00		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				450.00		
SUBTOTAL =				\$ 450.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$ 0.00		
TOTAL NATIONAL FEE =				\$ 450.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00		
TOTAL FEES ENCLOSED =				\$ 450.00		
				Amount to be refunded:	\$	
				Amount to be charged:	\$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>450.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>16-2463</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>						
<p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.</p>						
<p>SEND ALL CORRESPONDENCE TO: Price, Heneveld, Cooper, DeWitt & Litton, LLP 695 Kenmoor SE Post Office Box 2567 Grand Rapids, MI 49501</p>						
				 SIGNATURE		
				Marcus P. Dolce NAME		
				46 073 REGISTRATION NUMBER		

10/524476

Atty. Docket No. CCP01 P-300
Express Mail No. EV573205454US

DT01 Rec'd PCT/PTO 11 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Qiwang Xu et al.

For : THE USE OF N-ACETYL-D-GLUCOSAMINE FOR PREPARING
MEDICINES FOR UROGENITAL TRACT INFECTION'S
TREATMENT AND PREVENTION

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application, or credit any overpayment to Deposit Account No. 16-2463.

- 1) Any filing fees required under 35 USC §41(a)(1), (a)(3) and (d)(1) for which full payment has not been tendered.
- 2) Any patent application processing fees under 35 USC §41(a)(8) for which full payment has not been tendered.
- 3) Any assignment recording fee under 35 USC §41 (d)(2)(A) for which payment has not been tendered.

Pursuant to 37 C.F.R. §1.136(a)(3), the Commissioner is hereby authorized to treat any concurrent or future reply for this application that requires an extension of time as incorporating a request therefor. Any request or petition for an extension of time should be treated as requesting the appropriate length of time notwithstanding an inadvertent reference in the petition to a shorter period of time. A duplicate of this sheet is enclosed.

Respectfully submitted,

QIWANG XU ET AL.

By: Price, Heneveld, Cooper,
DeWitt & Litton, LLP

2/11/05
Date

MPD/msj

Marcus P. Dolce
Marcus P. Dolce
Registration No. 46 073
695 Kenmoor, S.E./Post Office Box 2567
Grand Rapids, Michigan 49501
(616) 949-9610